ICCM Share Price Performance
US$5.40
-22.20 (-80.44%)
120.4% overvalued intrinsic discount
US$2.45
Fair Value
Price US$5.40
AnalystHighTarget US$2.45
AnalystLowTarget US$1.00
AnalystConsensusTarget US$3.13
Fair ValueUS$2.45
Share Pricen/a
IceCure Medical Ltd Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 8 Fair Values set on narratives written by author
ICCM Community Narratives
AN
Fair Value
·Fair Value US$2.45 120.4% overvalued intrinsic discount
FDA Breast Cancer Clearance And Reimbursement Progress Will Transform Long Term Cryoablation Adoption
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$1 440.0% overvalued intrinsic discount
Regulatory And Reimbursement Delays Will Challenge Breast Cancer Adoption Yet Long Term Potential Will Build
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$3.13 72.8% overvalued intrinsic discount
Minimally Invasive Breast Cancer Adoption Will Drive Expanding Global Procedure Volumes
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
FDA Breast Cancer Clearance And Reimbursement Progress Will Transform Long Term Cryoablation Adoption
A new U.S. clearance and shifting medical guidance put IceCure’s ProSense on track to be used more often for certain early breast cancers, potentially moving it from a niche tool to a more routine option. The big question is whether doctors and hospitals adopt it quickly enough—while payment rules and real-world results are still being proven—to justify the company’s heavy push into the U.S.Read more
AN
US$2.45
120.4% overvalued intrinsic discount
Fair Value
Profit Margin
12.19%
Future PE
75.63x
Price in 2029
US$3.19
Regulatory And Reimbursement Delays Will Challenge Breast Cancer Adoption Yet Long Term Potential Will Build
Catalysts About IceCure Medical IceCure Medical develops and commercializes the ProSense cryoablation system for minimally invasive treatment of breast cancer and other tumors. What are the underlying business or industry changes driving this perspective?Read more
AN
US$1
440.0% overvalued intrinsic discount
Fair Value
Profit Margin
12.79%
Future PE
37.26x
Price in 2029
US$1.31
Minimally Invasive Breast Cancer Adoption Will Drive Expanding Global Procedure Volumes
Catalysts About IceCure Medical IceCure Medical develops and commercializes minimally invasive cryoablation systems for the treatment of breast and other tumors. What are the underlying business or industry changes driving this perspective?Read more
AN
US$3.13
72.8% overvalued intrinsic discount
Fair Value
Profit Margin
0.074%
Future PE
81.65x
Price in 2028
US$0.04
Trending Discussion
Recently Updated Narratives
AN
FDA Breast Cancer Clearance And Reimbursement Progress Will Transform Long Term Cryoablation Adoption
Fair Value: US$2.45 120.4% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Regulatory And Reimbursement Delays Will Challenge Breast Cancer Adoption Yet Long Term Potential Will Build
Fair Value: US$1 440.0% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Minimally Invasive Breast Cancer Adoption Will Drive Expanding Global Procedure Volumes
Fair Value: US$3.13 72.8% overvalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
IceCure Medical Ltd Key Details
About ICCM
- Founded
- 2006
- Employees
- 68
- CEO
- WebsiteView website
IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MSense, a multi probe system for the treatment of multiple and larger tumors. The company serves hospitals, interventional radiological centers, ambulatory centers, and private clinics. IceCure Medical Ltd was incorporated in 2006 and is headquartered in Caesarea, Israel.
